Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata

Rhinoconjunctivitis With or Without Allergic Asthma Clinical Trial

Official title: Observational Prospective Study to Assess the Safety and Effectiveness Profile of Beltavac® Polymerized With Alternaria Alternata

Status Completed

Clinical Trial Summary

Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerized With Alternaria alternata in allergic patients

Clinical Trial Description

This prospective open multi-centre non-interventional study assess the safety and effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac® Polymerized in Alternaria alternata allergic patients (children and adults) in routine medical care.

Patients receive a rush schedule administration every month for a year. They attend at least 4 study visits to inform about the adverse reactions, the self reported symptoms and the medication intake. ;

Related Conditions & MeSH terms

• Rhinoconjunctivitis With or Without Allergic Asthma

• NCT number: NCT03604718
• Study type: Observational
• Source: Probelte Pharma S.L.U.
• Status: Completed
• Start date: June 7, 2018
• Completion date: January 20, 2023